RareResearch.AI
← Back to atlas

E273A

Category 5 — IDR ExclusionConflictingCytoplasmic · predictedEditorial
GlutamateAlanine at position 273 · N-terminal cytoplasmic domain (87-313) · WFS1 (Wolframin)

Glutamate → Alanine at position 273 in N-terminal cytoplasmic domain. ClinVar Conflicting with broad spectrum — Cataract 41, DFNA6. AlphaMissense 0.12 (below threshold) — AM under-call. DynaMut2 ΔΔG +0.22. pLDDT 29 — Category 5 IDR! Same position as E273K.

Interactive 3D Structure

Wild-type reference
Wild-type E273 — native residue, no strong sidechain contacts
Fullscreen ↗
DynaMut2 mutant · E273A
Mutant A273 — energy-minimized; local contact network preserved
Fullscreen ↗

Computational Predictions

DynaMut2 ΔΔG
0.22kcal/mol
Stabilising — mild
AlphaMissense
0.123
LBen
AlphaFold pLDDT
29
model confidence
Schema
Cat 5
Category 5 — IDR Exclusion

Clinical Evidence

ClinVar classificationConflicting classifications of pathogenicity
Review statuscriteria provided, conflicting classifications
Associated conditionsCataract 41; Autosomal dominant nonsyndromic hearing loss 6 (DFNA6)
InheritanceAD multi-phenotype.
Population frequency (gnomAD v4)Ultra-rare · AF 0.0029%
cDNA changec.818A>C
ClinVar accessionVCV001614420
Last evaluated2025/09/22 00:00

Observed at very low frequency in gnomAD.

Structural Context

Position 273 same as E273K — DEEP IDR (pLDDT 29). DynaMut2 untrustworthy here.

E273A is the second substitution at 273 (with E273K). Both deep-IDR Category 5. AM 0.12 under-call; multi-phenotype confirms clinical pathogenicity.

Amino-acid chemistry
Glutamate (E) → Alanine (A) — charge lost + side chain reduced.
Position in the protein
N-terminal cytoplasmic domain · position 273 IDR (pLDDT 29 — deep IDR).

Druggability Assessment

Category 5 — IDR Exclusion. pLDDT 29 deep IDR. AlphaMissense 0.12 below threshold. DynaMut2 prediction not trustworthy.

The Atlas routes Category 5 variants to wet-lab characterization. Multi-phenotype confirms clinical pathogenicity.

Why this matters

E273A + E273K at same IDR position — both Cat 5, both flagged for wet-lab.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the E273A PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download E273A PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Region1321 · Interaction with ATP6V1A